Details: pack, label wording, sources, registration
Ardeaosmosol MA 10%, Solution
solution for infusion, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Emergency IV osmotherapy after haemodynamic stabilisation for raised intracranial pressure; short-term adjunct for acute glaucoma refractory to topical therapy. Not routine renal protection, edema treatment or forced diuresis.
6.6/10
Situational / acceptable
Details →
vetman assessment
Ardeaosmosol MA
×
10%, solution for infusion, human medicine
Assessed clinical scope Dog · Emergency IV osmotherapy after haemodynamic stabilisation for raised intracranial pressure; short-term adjunct for acute glaucoma refractory to topical therapy. Not routine renal protection, edema treatment or forced diuresis. · Intravenous
Care setting Emergency/intensive veterinary hospital care with reliable IV access, controlled filtered infusion and serial perfusion, neurologic/ophthalmic, urine-output, electrolyte, osmolality, renal and cardiopulmonary reassessment
vetman score
6.6/10
Situational / acceptable
Evidence confidence: Medium
Georgia: Yes, human · № რ-045183 · Verified on 16 Oct 2026
Off-label use
A legitimate hospital rescue osmotic agent for selected dogs with raised intracranial pressure and a short-term adjunct in acute glaucoma, but not a routine diuretic. Ten-percent solution doubles the dose volume versus 20%, and hypertonic saline may better preserve preload in some patients; stabilise perfusion first and monitor every bolus.
Regulatory and scientific credibility 7.0/10
This exact Ardeaosmosol Ma 10% solution has current Georgian and EU/EEA market evidence, an identifiable manufacturer and an accessible exact SmPC defining 100 mg/ml composition, IV use, containers, handling and risks. Its use in dogs and cats remains off-label and no veterinary authorisation was found.
Clinical efficacy 7.0/10
Current dog/cat fluid guidance supports 0.5–1 g/kg IV mannitol for traumatic brain injury, and canine clinical/physiologic studies show reduction of intracranial-pressure surrogates or describe predictable osmotic effects. It is also an accepted short-term adjunct for canine acute glaucoma. Comparative veterinary outcome evidence is limited, hypertonic saline is a credible alternative, and renal/edema claims lack strong current outcome support.
Safety and tolerability 6.0/10
The exact SmPC and class label make the major risks identifiable: initial intravascular expansion followed by diuresis, dehydration, sodium/potassium and acid-base disturbance, hypotension, pulmonary edema or heart failure, acute kidney injury, extravasation and rebound cerebral edema. With correct patient selection, slow measured bolus and intensive monitoring the margin is usable but not forgiving.
Clinical practicality 6.5/10
The 10% ready-to-infuse solution avoids dilution and permits precise pump delivery, but the usual 0.5–1 g/kg emergency dose requires 5–10 ml/kg—twice the volume of a 20% solution—plus dependable IV access, a filter and close monitoring. Large single containers can create waste and contamination risk after withdrawal for a smaller patient.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not administer to an anuric, severely dehydrated or inadequately resuscitated patient, or one with severe pulmonary congestion/edema. Correct hypovolaemia and major fluid, electrolyte and acid-base abnormalities first; mannitol-induced diuresis can worsen hypotension and cerebral perfusion. Stop or reassess immediately if urine output fails, azotaemia/acute kidney injury worsens, pulmonary edema, heart failure, hypotension or neurologic deterioration develops. Track urine output, perfusion, body weight, electrolytes, acid-base status, creatinine, serum osmolality and cardiopulmonary findings around every dose. Use intermittent measured boluses, not a prolonged continuous infusion, for cerebral edema. Repeated/high exposure or a disrupted blood-brain barrier can permit tissue accumulation and rebound intracranial pressure; repeat only after documented response and reassessment. Inspect the solution for crystals, haze, colour change, particles, leaks and container damage. Do not infuse visible crystals; follow the exact product instructions for safe warming/dissolution and cooling, and use a final in-line filter because crystals can form during storage. Hypertonic saline is a credible alternative for raised intracranial pressure and may better avoid diuresis and preserve or increase preload. Select between agents from volume status, sodium/osmolality, renal/cardiac function and response—not from habit or brand availability. For acute glaucoma this is a short-term pressure-lowering adjunct, not definitive treatment. Start appropriate topical therapy and urgent ophthalmic assessment; evidence is strongest in dogs, while feline efficacy and secondary glaucoma with a permeable blood-aqueous barrier are less certain. Do not use mannitol routinely to “protect” kidneys, convert established anuria, mobilise generalized edema or force diuresis without a defined toxin-specific rationale. Adequate renal blood flow and filtration are required, and absent response to a test dose is a stop signal rather than a reason to escalate blindly. Do not add mannitol to whole blood or run it through the same administration set as blood. Do not assume Y-site or additive compatibility; concentrated mannitol can precipitate with electrolytes, and concurrent nephrotoxic or additional potassium-depleting diuretic therapy requires explicit risk review and monitoring. Veterinary pregnancy and lactation safety is not established. Mannitol crosses the placenta and milk excretion is uncertain; in a pregnant or nursing patient use only when the emergency maternal benefit clearly outweighs fetal/neonatal uncertainty. Ardeaosmosol has an accessible exact SmPC; Mani-Tek does not in the reviewed public sources. Container size, material, ports, storage, warming, filtration and post-opening rules must therefore be verified from the exact pack before use; shared ingredient and concentration do not prove identical handling. Assessment sources +
Close
Cat
Emergency IV osmotherapy after haemodynamic stabilisation for raised intracranial pressure; short-term adjunct for acute glaucoma refractory to topical therapy. Not routine renal protection, edema treatment or forced diuresis.
6.4/10
Situational / acceptable
Details →
vetman assessment
Ardeaosmosol MA
×
10%, solution for infusion, human medicine
Assessed clinical scope Cat · Emergency IV osmotherapy after haemodynamic stabilisation for raised intracranial pressure; short-term adjunct for acute glaucoma refractory to topical therapy. Not routine renal protection, edema treatment or forced diuresis. · Intravenous
Care setting Emergency/intensive veterinary hospital care with reliable IV access, controlled filtered infusion and serial perfusion, neurologic/ophthalmic, urine-output, electrolyte, osmolality, renal and cardiopulmonary reassessment
vetman score
6.4/10
Situational / acceptable
Evidence confidence: Medium
Georgia: Yes, human · № რ-045183 · Verified on 16 Oct 2026
Off-label use
A plausible hospital rescue osmotic agent for selected cats with raised intracranial pressure, but direct feline outcome evidence and glaucoma data are sparse. Ten-percent solution has a meaningful volume burden; stabilise perfusion first, use a filtered measured bolus and monitor closely rather than treating it as a routine diuretic.
Regulatory and scientific credibility 7.0/10
This exact Ardeaosmosol Ma 10% solution has current Georgian and EU/EEA market evidence, an identifiable manufacturer and an accessible exact SmPC defining 100 mg/ml composition, IV use, containers, handling and risks. Its use in dogs and cats remains off-label and no veterinary authorisation was found.
Clinical efficacy 6.5/10
Current dog/cat guidance includes IV mannitol for traumatic brain injury, but direct feline clinical evidence is extremely small: the prospective natural-disease pilot included only two cats and one dog. The osmotic mechanism is plausible and established, yet feline outcome and glaucoma evidence are largely extrapolated; renal/edema claims lack strong current outcome support.
Safety and tolerability 6.0/10
The exact SmPC and class label make the major risks identifiable: initial intravascular expansion followed by diuresis, dehydration, sodium/potassium and acid-base disturbance, hypotension, pulmonary edema or heart failure, acute kidney injury, extravasation and rebound cerebral edema. With correct patient selection, slow measured bolus and intensive monitoring the margin is usable but not forgiving.
Clinical practicality 6.0/10
The 10% ready-to-infuse solution avoids dilution, but at 5–10 ml/kg the emergency dose is relatively bulky for a cat and must be balanced against cerebral perfusion and volume status. Accurate pump delivery, a filter and intensive monitoring are required, while a large human infusion container creates substantial residual-volume and asepsis burden.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not administer to an anuric, severely dehydrated or inadequately resuscitated patient, or one with severe pulmonary congestion/edema. Correct hypovolaemia and major fluid, electrolyte and acid-base abnormalities first; mannitol-induced diuresis can worsen hypotension and cerebral perfusion. Stop or reassess immediately if urine output fails, azotaemia/acute kidney injury worsens, pulmonary edema, heart failure, hypotension or neurologic deterioration develops. Track urine output, perfusion, body weight, electrolytes, acid-base status, creatinine, serum osmolality and cardiopulmonary findings around every dose. Use intermittent measured boluses, not a prolonged continuous infusion, for cerebral edema. Repeated/high exposure or a disrupted blood-brain barrier can permit tissue accumulation and rebound intracranial pressure; repeat only after documented response and reassessment. Inspect the solution for crystals, haze, colour change, particles, leaks and container damage. Do not infuse visible crystals; follow the exact product instructions for safe warming/dissolution and cooling, and use a final in-line filter because crystals can form during storage. Hypertonic saline is a credible alternative for raised intracranial pressure and may better avoid diuresis and preserve or increase preload. Select between agents from volume status, sodium/osmolality, renal/cardiac function and response—not from habit or brand availability. For acute glaucoma this is a short-term pressure-lowering adjunct, not definitive treatment. Start appropriate topical therapy and urgent ophthalmic assessment; evidence is strongest in dogs, while feline efficacy and secondary glaucoma with a permeable blood-aqueous barrier are less certain. Do not use mannitol routinely to “protect” kidneys, convert established anuria, mobilise generalized edema or force diuresis without a defined toxin-specific rationale. Adequate renal blood flow and filtration are required, and absent response to a test dose is a stop signal rather than a reason to escalate blindly. Do not add mannitol to whole blood or run it through the same administration set as blood. Do not assume Y-site or additive compatibility; concentrated mannitol can precipitate with electrolytes, and concurrent nephrotoxic or additional potassium-depleting diuretic therapy requires explicit risk review and monitoring. Veterinary pregnancy and lactation safety is not established. Mannitol crosses the placenta and milk excretion is uncertain; in a pregnant or nursing patient use only when the emergency maternal benefit clearly outweighs fetal/neonatal uncertainty. Ardeaosmosol has an accessible exact SmPC; Mani-Tek does not in the reviewed public sources. Container size, material, ports, storage, warming, filtration and post-opening rules must therefore be verified from the exact pack before use; shared ingredient and concentration do not prove identical handling. Assessment sources +
Close
Administration route
Intravenous
Registration
Georgia
Yes, human
In force until 07 Apr 2031
Human (Ministry of Health, RAMA)
In the register: არდეაოსმოსოლ MA 10%, საინფუზიო ხსნარი, ადამიანის პრეპარატი
№ რ-045183
Verified on: 16 Oct 2026
EU
Yes, human
UK
No
US
No
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
